Identification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancer

Understanding the association of pyroptosis with tumor progression, prognosis and effect on immunotherapeutic response in breast cancer (BC) is limited. This study analysed forty pyroptosis-related genes to construct the pyroptosis score. Association of the pyroptosis score with the overall survival...

Full description

Saved in:
Bibliographic Details
Published inScientific reports Vol. 12; no. 1; pp. 10640 - 15
Main Authors Huang, Guo, Zhou, Jun, Chen, Juan, Liu, Guowen
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 23.06.2022
Nature Publishing Group
Nature Portfolio
Subjects
631/250
631/67/1347
692/4028
692/499
Breast cancer
Humanities and Social Sciences
Immunosuppressive agents
Immunotherapy
Infiltration
Medical prognosis
Metastases
multidisciplinary
Mutation
p53 Protein
Patients
Prognosis
Pyroptosis
Science
Science (multidisciplinary)
Tumor microenvironment
Tumors
Online AccessGet full text

Cover

Abstract Understanding the association of pyroptosis with tumor progression, prognosis and effect on immunotherapeutic response in breast cancer (BC) is limited. This study analysed forty pyroptosis-related genes to construct the pyroptosis score. Association of the pyroptosis score with the overall survival, clinical features, tumor mutation load, immune cell infiltration, and treatment sensitivity of patients with BC was analysed. Out of 983 BC samples, 304 (30.93%) had genetic alterations with the highest TP53 frequency. We identified three separate subtypes associated with pyroptosis action. These subtypes correlate with the clinicopathological characteristics, TME immune cell infiltration, and disease prognosis. Based on the expression levels of the pyroptosis genes, we divided the pyroptosis score into a high group and a low group. The immune-activated pyroptosis subtype had a higher score with a better prognosis. We also observed that the pyroptosis score correlates with the tumor mutation burden. The pyroptosis score and disease prognosis were directly proportional. A higher pyroptosis score indicated a better prognosis. Results suggest that the pyroptosis-related gene prognosis model is closely related to the immune cell infiltration of BC. The three pyroptosis subtypes associated with BC assist in accurately identifying the tumor subtype, the prognosis of immunotherapy drugs and the patient’s therapeutic response.
AbstractList Understanding the association of pyroptosis with tumor progression, prognosis and effect on immunotherapeutic response in breast cancer (BC) is limited. This study analysed forty pyroptosis-related genes to construct the pyroptosis score. Association of the pyroptosis score with the overall survival, clinical features, tumor mutation load, immune cell infiltration, and treatment sensitivity of patients with BC was analysed. Out of 983 BC samples, 304 (30.93%) had genetic alterations with the highest TP53 frequency. We identified three separate subtypes associated with pyroptosis action. These subtypes correlate with the clinicopathological characteristics, TME immune cell infiltration, and disease prognosis. Based on the expression levels of the pyroptosis genes, we divided the pyroptosis score into a high group and a low group. The immune-activated pyroptosis subtype had a higher score with a better prognosis. We also observed that the pyroptosis score correlates with the tumor mutation burden. The pyroptosis score and disease prognosis were directly proportional. A higher pyroptosis score indicated a better prognosis. Results suggest that the pyroptosis-related gene prognosis model is closely related to the immune cell infiltration of BC. The three pyroptosis subtypes associated with BC assist in accurately identifying the tumor subtype, the prognosis of immunotherapy drugs and the patient’s therapeutic response.
Understanding the association of pyroptosis with tumor progression, prognosis and effect on immunotherapeutic response in breast cancer (BC) is limited. This study analysed forty pyroptosis-related genes to construct the pyroptosis score. Association of the pyroptosis score with the overall survival, clinical features, tumor mutation load, immune cell infiltration, and treatment sensitivity of patients with BC was analysed. Out of 983 BC samples, 304 (30.93%) had genetic alterations with the highest TP53 frequency. We identified three separate subtypes associated with pyroptosis action. These subtypes correlate with the clinicopathological characteristics, TME immune cell infiltration, and disease prognosis. Based on the expression levels of the pyroptosis genes, we divided the pyroptosis score into a high group and a low group. The immune-activated pyroptosis subtype had a higher score with a better prognosis. We also observed that the pyroptosis score correlates with the tumor mutation burden. The pyroptosis score and disease prognosis were directly proportional. A higher pyroptosis score indicated a better prognosis. Results suggest that the pyroptosis-related gene prognosis model is closely related to the immune cell infiltration of BC. The three pyroptosis subtypes associated with BC assist in accurately identifying the tumor subtype, the prognosis of immunotherapy drugs and the patient's therapeutic response.Understanding the association of pyroptosis with tumor progression, prognosis and effect on immunotherapeutic response in breast cancer (BC) is limited. This study analysed forty pyroptosis-related genes to construct the pyroptosis score. Association of the pyroptosis score with the overall survival, clinical features, tumor mutation load, immune cell infiltration, and treatment sensitivity of patients with BC was analysed. Out of 983 BC samples, 304 (30.93%) had genetic alterations with the highest TP53 frequency. We identified three separate subtypes associated with pyroptosis action. These subtypes correlate with the clinicopathological characteristics, TME immune cell infiltration, and disease prognosis. Based on the expression levels of the pyroptosis genes, we divided the pyroptosis score into a high group and a low group. The immune-activated pyroptosis subtype had a higher score with a better prognosis. We also observed that the pyroptosis score correlates with the tumor mutation burden. The pyroptosis score and disease prognosis were directly proportional. A higher pyroptosis score indicated a better prognosis. Results suggest that the pyroptosis-related gene prognosis model is closely related to the immune cell infiltration of BC. The three pyroptosis subtypes associated with BC assist in accurately identifying the tumor subtype, the prognosis of immunotherapy drugs and the patient's therapeutic response.
Abstract Understanding the association of pyroptosis with tumor progression, prognosis and effect on immunotherapeutic response in breast cancer (BC) is limited. This study analysed forty pyroptosis-related genes to construct the pyroptosis score. Association of the pyroptosis score with the overall survival, clinical features, tumor mutation load, immune cell infiltration, and treatment sensitivity of patients with BC was analysed. Out of 983 BC samples, 304 (30.93%) had genetic alterations with the highest TP53 frequency. We identified three separate subtypes associated with pyroptosis action. These subtypes correlate with the clinicopathological characteristics, TME immune cell infiltration, and disease prognosis. Based on the expression levels of the pyroptosis genes, we divided the pyroptosis score into a high group and a low group. The immune-activated pyroptosis subtype had a higher score with a better prognosis. We also observed that the pyroptosis score correlates with the tumor mutation burden. The pyroptosis score and disease prognosis were directly proportional. A higher pyroptosis score indicated a better prognosis. Results suggest that the pyroptosis-related gene prognosis model is closely related to the immune cell infiltration of BC. The three pyroptosis subtypes associated with BC assist in accurately identifying the tumor subtype, the prognosis of immunotherapy drugs and the patient’s therapeutic response.
ArticleNumber 10640
Author Liu, Guowen
Zhou, Jun
Huang, Guo
Chen, Juan
Author_xml – sequence: 1
  givenname: Guo
  surname: Huang
  fullname: Huang, Guo
  organization: Hengyang Medical School, University of South China, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, Cancer Research Institute, University of South China
– sequence: 2
  givenname: Jun
  surname: Zhou
  fullname: Zhou, Jun
  organization: Hengyang Medical School, University of South China, Key Laboratory of Tumor Cellular and Molecular Pathology, College of Hunan Province, Cancer Research Institute, University of South China
– sequence: 3
  givenname: Juan
  surname: Chen
  fullname: Chen, Juan
  email: chenjuan@usc.edu.cn
  organization: The Second Affiliated Hospital, Department of Radiotherapy, Hengyang Medical School, University of South China
– sequence: 4
  givenname: Guowen
  surname: Liu
  fullname: Liu, Guowen
  email: liugw8318@163.com
  organization: Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital
BookMark eNp9Uktv3CAYtKpUzaP5Az1Z6qUXt7xs4FKpivpYKVIv7Rl95rFhZcMW8Er770vWUZvkEC4gmBkGZi6bsxCDbZp3GH3EiIpPmeFeig4R0mEmJO_wq-aCINZ3hBJy9mh93lznvEN19EQyLN8057TnVGJBLprDxthQvPMaio-hja7dH1Pcl5h9bpOdoFjT5mUsx73NLQTTlmWOqZ29TtGGg08xzFWi9cH5qaRVRt9BAl1s8rl4nethOyYLubQagrbpbfPawZTt9cN81fz-9vXXzY_u9uf3zc2X2073mJeuH4AOhAOWTupRMicYIgCWIzNazTCggRihKXeyx1JzLO1osJCGOgLIAL1qNquuibBT--RnSEcVwavTRkxbBak6nKzirMfODdqNjDI6wKitcSMZaC-EcIRWrc-r1n4ZZ2t0fXSC6Yno05Pg79Q2HpQkZEAngQ8PAin-WWwuavZZ22mCYOOSFRkERgzV3Cr0_TPoLi4p1K-qKC4lv0-wosiKqlHknKz7ZwYjdd8StbZE1ZaoU0sUriTxjKR9OaVWTfvpZSpdqbneE7Y2_Xf1AusvYbrVxQ
CitedBy_id crossref_primary_10_1038_s41420_025_02376_1
crossref_primary_10_1007_s10495_023_01823_7
crossref_primary_10_1038_s41598_022_25231_0
crossref_primary_10_18632_aging_205946
crossref_primary_10_3389_fimmu_2023_1171811
crossref_primary_10_4251_wjgo_v16_i8_3410
crossref_primary_10_1038_s41598_024_75650_4
crossref_primary_10_1155_2022_2515525
crossref_primary_10_1002_tox_24205
Cites_doi 10.1016/j.canlet.2021.09.035
10.1038/nrg3871
10.1016/j.redox.2019.101239
10.1177/0962280219856238
10.1038/s41586-020-2079-1
10.1016/j.imbio.2021.152068
10.1016/j.bbrc.2017.11.156
10.1038/nchembio.2229
10.1016/s1470-2045(14)71116-7
10.1080/2162402x.2020.1865670
10.1080/13543784.2022.2008354
10.18632/aging.203855
10.2147/jir.S349186
10.1126/science.aaz7548
10.1038/s41598-020-61710-y
10.1016/j.ccell.2020.04.007
10.1093/nar/gkaa970
10.15252/emmm.202013452
10.1016/j.ejca.2021.02.028
10.1111/imr.12287
10.3389/fcell.2021.697832
10.1634/theoncologist.2012-0397
10.1039/d1nr05001j
10.1038/s41591-018-0014-x
10.3389/fimmu.2021.720877
10.1016/j.semcancer.2015.03.001
10.3390/genes12101535
10.1016/j.ymeth.2017.06.010
10.3389/fimmu.2021.650491
10.1038/nmeth.3337
10.3389/fgene.2021.763807
10.1093/annonc/mds280
10.1038/s41571-021-00471-7
10.3389/fimmu.2021.748221
10.1186/s13054-021-03775-3
10.1016/j.phrs.2021.105748
10.1111/imr.12908
10.1001/jama.2021.1647
10.1016/j.molcel.2019.09.006
10.1038/ncomms14128
10.1186/s12935-020-01472-9
10.1038/s41467-020-19810-w
10.1080/14728222.2021.2006187
10.1186/1471-2407-11-143
10.1016/s1470-2045(21)00420-4
10.1126/science.aar7607
10.1002/jcla.24292
10.1111/jcmm.16574
10.1016/j.jid.2021.09.030
10.1016/j.annonc.2022.02.008
10.1093/annonc/mdy495
10.3322/caac.21492
10.1016/j.neo.2021.05.016
10.1038/s41419-019-1883-8
10.1073/pnas.0506580102
10.2147/jir.S338584
10.1016/s1470-2045(20)30754-3
10.1158/0008-5472.Can-19-0573
10.1016/j.breast.2016.07.015
10.1016/s1470-2045(20)30445-9
10.1186/s13046-021-02065-8
10.18632/aging.203687
10.1093/carcin/bgt208
10.1111/bjd.20748
10.1038/s41467-020-19933-0
10.1001/jamaoncol.2021.1932
10.1016/s1470-2045(14)70080-4
10.3389/fcell.2021.780142
10.1038/srep36107
10.3322/caac.21565
10.1155/2022/4494713
ContentType Journal Article
Copyright The Author(s) 2022
The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2022. The Author(s).
Copyright_xml – notice: The Author(s) 2022
– notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2022. The Author(s).
DBID C6C
AAYXX
CITATION
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-022-14897-1
DatabaseName Springer Nature OA Free Journals
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature Link
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 15
ExternalDocumentID oai_doaj_org_article_7451ff6cfb43436abcedfb2635888f23
PMC9226023
10_1038_s41598_022_14897_1
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFPKN
CITATION
PHGZM
PHGZT
7XB
8FK
AARCD
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c517t-56a3627a19f9cb94f8402aae70dbec41a062d8c37f9519c719ebd189d3f2a0da3
IEDL.DBID M48
ISSN 2045-2322
IngestDate Wed Aug 27 01:15:49 EDT 2025
Thu Aug 21 18:28:03 EDT 2025
Tue Aug 05 09:50:12 EDT 2025
Wed Aug 13 05:15:33 EDT 2025
Tue Jul 01 04:16:43 EDT 2025
Thu Apr 24 23:12:23 EDT 2025
Fri Feb 21 02:40:17 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c517t-56a3627a19f9cb94f8402aae70dbec41a062d8c37f9519c719ebd189d3f2a0da3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41598-022-14897-1
PMID 35739182
PQID 2679973573
PQPubID 2041939
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_7451ff6cfb43436abcedfb2635888f23
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9226023
proquest_miscellaneous_2681040045
proquest_journals_2679973573
crossref_primary_10_1038_s41598_022_14897_1
crossref_citationtrail_10_1038_s41598_022_14897_1
springer_journals_10_1038_s41598_022_14897_1
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-06-23
PublicationDateYYYYMMDD 2022-06-23
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-06-23
  day: 23
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationYear 2022
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Pérol (CR66) 2022; 33
Guo, Fu, Zhang, Liu, Li (CR57) 2016; 6
Marabelle (CR68) 2020; 21
Jatoi, Kemp (CR3) 2021; 325
Corti, Nicolò, Curigliano (CR26) 2021; 25
Kanehisa, Furumichi, Sato, Ishiguro-Watanabe, Tanabe (CR35) 2021; 49
Clarke (CR32) 2013; 34
Kaboli, Imani, Jomhori, Ling (CR45) 2021; 11
Wang (CR56) 2021; 14
Moaaz, Lotfy, Motawea, Fadali (CR24) 2021; 226
Zhang (CR47) 2021; 25
Xiang (CR60) 2021; 12
Yu (CR40) 2022; 14
Miller (CR9) 2019; 69
Pariyar, Johns, Thorne, Scott, Avery-Kiejda (CR51) 2021; 23
Li, Pak, Todem (CR38) 2020; 29
Xia (CR28) 2019; 10
Yuan (CR16) 2021; 170
Wang (CR55) 2018; 495
Rühl (CR11) 2018; 362
Xu, Hu, Liu (CR41) 2022; 15
Yung, Davidson (CR6) 2021; 22
Wang (CR71) 2020; 579
Winer (CR64) 2021; 22
Binnewies (CR23) 2018; 24
Vaidya (CR5) 2021; 18
Okondo (CR22) 2017; 13
Chan (CR58) 2019; 30
Luen, Virassamy, Savas, Salgado, Loi (CR59) 2016; 29
Park (CR4) 2020; 11
Prat (CR31) 2013; 18
Cao (CR13) 2021; 12
Gao (CR25) 2021; 12
Robinson (CR48) 2019; 26
Bray (CR1) 2018; 68
Watanabe, Guo, Kamada (CR14) 2021; 13
Xie (CR54) 2021; 13
Deng (CR62) 2022; 36
Chauhan, Vande Walle, Lamkanfi (CR21) 2020; 297
Gianni (CR2) 2014; 15
Liu, Wang, Genchev, Lu (CR37) 2017; 124
Rizzo, Ricci (CR27) 2022; 31
Zhou (CR63) 2021; 12
Subramanian (CR34) 2005; 102
Zarrei, MacDonald, Merico, Scherer (CR50) 2015; 16
Rogers (CR49) 2017; 8
Mei, Zhao, Fu (CR53) 2020; 10
Legrand, Konstantinou, Goode, Meier (CR20) 2019; 76
Mohammad (CR46) 2015
Jiao (CR15) 2021; 25
Meng (CR61) 2021; 13
Ribas (CR67) 2020; 11
Savas, Loi (CR8) 2020; 37
Bi, Chen, Yang (CR43) 2020; 20
Kao, Chang, Hsu, Huang (CR29) 2011; 11
Nie (CR69) 2021; 10
Shangguan (CR18) 2021; 9
Prabakaran (CR52) 2019; 79
Pérez-García (CR65) 2021; 148
Wu, Zhu, Luo, Li (CR39) 2021; 12
Hatschek (CR7) 2021; 7
Newman (CR42) 2015; 12
Loveless, Bloomquist, Teng (CR70) 2021; 40
Zhou (CR72) 2020
Balachandran, Gonen, Smith, DeMatteo (CR44) 2015; 16
Abbas (CR36) 2022; 186
Wu (CR12) 2021; 9
Metzger-Filho (CR30) 2013; 24
Chen (CR33) 2022; 2022
Ahmed (CR17) 2022; 142
Zheng (CR19) 2021; 522
Jorgensen, Miao (CR10) 2015; 265
A Rizzo (14897_CR27) 2022; 31
H Yu (14897_CR40) 2022; 14
F Shangguan (14897_CR18) 2021; 9
Y Wang (14897_CR55) 2018; 495
S Rühl (14897_CR11) 2018; 362
Z Zhou (14897_CR63) 2021; 12
K Kao (14897_CR29) 2011; 11
C Corti (14897_CR26) 2021; 25
J Pérez-García (14897_CR65) 2021; 148
A Legrand (14897_CR20) 2019; 76
C Liu (14897_CR37) 2017; 124
T Chan (14897_CR58) 2019; 30
M Pérol (14897_CR66) 2022; 33
J Vaidya (14897_CR5) 2021; 18
C Clarke (14897_CR32) 2013; 34
F Bray (14897_CR1) 2018; 68
F Bi (14897_CR43) 2020; 20
X Xia (14897_CR28) 2019; 10
D Chauhan (14897_CR21) 2020; 297
L Abbas (14897_CR36) 2022; 186
J Wu (14897_CR12) 2021; 9
A Prat (14897_CR31) 2013; 18
W Nie (14897_CR69) 2021; 10
R Yung (14897_CR6) 2021; 22
R Yuan (14897_CR16) 2021; 170
S Luen (14897_CR59) 2016; 29
M Kanehisa (14897_CR35) 2021; 49
B Guo (14897_CR57) 2016; 6
Y Park (14897_CR4) 2020; 11
O Metzger-Filho (14897_CR30) 2013; 24
Y Jiao (14897_CR15) 2021; 25
F Ahmed (14897_CR17) 2022; 142
A Marabelle (14897_CR68) 2020; 21
K Miller (14897_CR9) 2019; 69
J Wu (14897_CR39) 2021; 12
N Robinson (14897_CR48) 2019; 26
I Prabakaran (14897_CR52) 2019; 79
R Xiang (14897_CR60) 2021; 12
C Gao (14897_CR25) 2021; 12
E Winer (14897_CR64) 2021; 22
D Watanabe (14897_CR14) 2021; 13
C Rogers (14897_CR49) 2017; 8
I Jorgensen (14897_CR10) 2015; 265
J Meng (14897_CR61) 2021; 13
H Cao (14897_CR13) 2021; 12
P Savas (14897_CR8) 2020; 37
V Balachandran (14897_CR44) 2015; 16
J Wang (14897_CR56) 2021; 14
Q Wang (14897_CR71) 2020; 579
R Loveless (14897_CR70) 2021; 40
J Chen (14897_CR33) 2022; 2022
T Hatschek (14897_CR7) 2021; 7
A Newman (14897_CR42) 2015; 12
A Subramanian (14897_CR34) 2005; 102
H Deng (14897_CR62) 2022; 36
A Ribas (14897_CR67) 2020; 11
C Li (14897_CR38) 2020; 29
M Zarrei (14897_CR50) 2015; 16
M Binnewies (14897_CR23) 2018; 24
P Kaboli (14897_CR45) 2021; 11
M Okondo (14897_CR22) 2017; 13
R Mohammad (14897_CR46) 2015
L Gianni (14897_CR2) 2014; 15
M Moaaz (14897_CR24) 2021; 226
I Jatoi (14897_CR3) 2021; 325
L Xu (14897_CR41) 2022; 15
M Pariyar (14897_CR51) 2021; 23
Z Zhou (14897_CR72) 2020
J Mei (14897_CR53) 2020; 10
Z Zheng (14897_CR19) 2021; 522
B Xie (14897_CR54) 2021; 13
Z Zhang (14897_CR47) 2021; 25
References_xml – volume: 522
  start-page: 171
  year: 2021
  end-page: 183
  ident: CR19
  article-title: STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2021.09.035
– volume: 16
  start-page: 172
  year: 2015
  end-page: 183
  ident: CR50
  article-title: A copy number variation map of the human genome
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg3871
– volume: 26
  start-page: 101239
  year: 2019
  ident: CR48
  article-title: Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos
  publication-title: Redox Biol.
  doi: 10.1016/j.redox.2019.101239
– volume: 29
  start-page: 1243
  year: 2020
  end-page: 1255
  ident: CR38
  article-title: Adaptive lasso for the Cox regression with interval censored and possibly left truncated data
  publication-title: Stat. Methods Med. Res.
  doi: 10.1177/0962280219856238
– volume: 579
  start-page: 421
  year: 2020
  end-page: 426
  ident: CR71
  article-title: A bioorthogonal system reveals antitumour immune function of pyroptosis
  publication-title: Nature
  doi: 10.1038/s41586-020-2079-1
– volume: 226
  start-page: 152068
  year: 2021
  ident: CR24
  article-title: The interplay of interleukin-17A and breast cancer tumor microenvironment as a novel immunotherapeutic approach to increase tumor immunogenicity
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2021.152068
– volume: 495
  start-page: 1418
  year: 2018
  end-page: 1425
  ident: CR55
  article-title: GSDME mediates caspase-3-dependent pyroptosis in gastric cancer
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2017.11.156
– volume: 13
  start-page: 46
  year: 2017
  end-page: 53
  ident: CR22
  article-title: DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/nchembio.2229
– volume: 16
  start-page: e173
  year: 2015
  end-page: e180
  ident: CR44
  article-title: Nomograms in oncology: More than meets the eye
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(14)71116-7
– volume: 10
  start-page: 1865670
  year: 2021
  ident: CR69
  article-title: STK11Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring or mutation
  publication-title: Oncoimmunology
  doi: 10.1080/2162402x.2020.1865670
– volume: 31
  start-page: 549
  year: 2022
  end-page: 555
  ident: CR27
  article-title: Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
  publication-title: Expert Opin. Investig. Drugs
  doi: 10.1080/13543784.2022.2008354
– volume: 14
  start-page: 989
  year: 2022
  end-page: 1013
  ident: CR40
  article-title: A novel pyroptosis-related signature predicts prognosis and response to treatment in breast carcinoma
  publication-title: Aging
  doi: 10.18632/aging.203855
– volume: 15
  start-page: 345
  year: 2022
  end-page: 362
  ident: CR41
  article-title: Pyroptosis-mediated molecular subtypes are characterized by distinct tumor microenvironment infiltration characteristics in breast cancer
  publication-title: J. Inflamm. Res.
  doi: 10.2147/jir.S349186
– year: 2020
  ident: CR72
  article-title: Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells
  publication-title: Science (New York).
  doi: 10.1126/science.aaz7548
– volume: 10
  start-page: 4800
  year: 2020
  ident: CR53
  article-title: Molecular classification of breast cancer using the mRNA expression profiles of immune-related genes
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-61710-y
– volume: 37
  start-page: 623
  year: 2020
  end-page: 624
  ident: CR8
  article-title: Expanding the role for immunotherapy in triple-negative breast cancer
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.04.007
– volume: 49
  start-page: D545
  year: 2021
  end-page: D551
  ident: CR35
  article-title: KEGG: Integrating viruses and cellular organisms
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkaa970
– volume: 13
  start-page: e13452
  year: 2021
  ident: CR14
  article-title: Interaction between the inflammasome and commensal microorganisms in gastrointestinal health and disease
  publication-title: EMBO Mol. Med.
  doi: 10.15252/emmm.202013452
– volume: 148
  start-page: 382
  year: 2021
  end-page: 394
  ident: CR65
  article-title: Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
  publication-title: Eur. J. Cancer (Oxford)
  doi: 10.1016/j.ejca.2021.02.028
– volume: 265
  start-page: 130
  year: 2015
  end-page: 142
  ident: CR10
  article-title: Pyroptotic cell death defends against intracellular pathogens
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12287
– volume: 9
  start-page: 697832
  year: 2021
  ident: CR18
  article-title: A novel mechanism of cannabidiol in suppressing hepatocellular carcinoma by inducing GSDME dependent pyroptosis
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.697832
– volume: 18
  start-page: 123
  year: 2013
  end-page: 133
  ident: CR31
  article-title: Molecular characterization of basal-like and non-basal-like triple-negative breast cancer
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2012-0397
– volume: 13
  start-page: 18608
  year: 2021
  end-page: 18615
  ident: CR54
  article-title: Combination of DNA demethylation and chemotherapy to trigger cell pyroptosis for inhalation treatment of lung cancer
  publication-title: Nanoscale
  doi: 10.1039/d1nr05001j
– volume: 24
  start-page: 541
  year: 2018
  end-page: 550
  ident: CR23
  article-title: Understanding the tumor immune microenvironment (TIME) for effective therapy
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0014-x
– volume: 12
  start-page: 720877
  year: 2021
  ident: CR13
  article-title: Novel effects of combination therapy through inhibition of caspase-1/gasdermin D induced-pyroptosis in lupus nephritis
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.720877
– year: 2015
  ident: CR46
  article-title: Broad targeting of resistance to apoptosis in cancer
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2015.03.001
– volume: 12
  start-page: 1535
  year: 2021
  ident: CR60
  article-title: Pyroptosis patterns characterized by distinct tumor microenvironment infiltration landscapes in gastric cancer
  publication-title: Genes
  doi: 10.3390/genes12101535
– volume: 124
  start-page: 100
  year: 2017
  end-page: 107
  ident: CR37
  article-title: Multi-omics facilitated variable selection in Cox-regression model for cancer prognosis prediction
  publication-title: Methods (San Diego)
  doi: 10.1016/j.ymeth.2017.06.010
– volume: 12
  start-page: 650491
  year: 2021
  ident: CR25
  article-title: Tumor mutation burden and immune invasion characteristics in triple negative breast cancer: Genome high-throughput data analysis
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.650491
– volume: 12
  start-page: 453
  year: 2015
  end-page: 457
  ident: CR42
  article-title: Robust enumeration of cell subsets from tissue expression profiles
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.3337
– volume: 12
  start-page: 763807
  year: 2021
  ident: CR63
  article-title: Comprehensive characterization of pyroptosis patterns with implications in prognosis and immunotherapy in low-grade gliomas
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2021.763807
– volume: 24
  start-page: 377
  year: 2013
  end-page: 384
  ident: CR30
  article-title: Genomic grade adds prognostic value in invasive lobular carcinoma
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mds280
– volume: 18
  start-page: 187
  year: 2021
  end-page: 188
  ident: CR5
  article-title: Intraoperative radiotherapy for breast cancer: Powerful evidence to change practice
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-021-00471-7
– volume: 12
  start-page: 748221
  year: 2021
  ident: CR39
  article-title: Comprehensive analysis of pyroptosis-related genes and tumor microenvironment infiltration characterization in breast cancer
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.748221
– volume: 25
  start-page: 356
  year: 2021
  ident: CR15
  article-title: Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury
  publication-title: Crit. Care (London)
  doi: 10.1186/s13054-021-03775-3
– volume: 170
  start-page: 105748
  year: 2021
  ident: CR16
  article-title: Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4/NLRP3/GSDMD-dependent pyroptosis
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2021.105748
– volume: 297
  start-page: 123
  year: 2020
  end-page: 138
  ident: CR21
  article-title: Therapeutic modulation of inflammasome pathways
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12908
– volume: 325
  start-page: 1804
  year: 2021
  ident: CR3
  article-title: Surgery for breast cancer prevention
  publication-title: JAMA
  doi: 10.1001/jama.2021.1647
– volume: 76
  start-page: 232
  year: 2019
  end-page: 242
  ident: CR20
  article-title: The diversification of cell death and immunity: Memento mori
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2019.09.006
– volume: 8
  start-page: 14128
  year: 2017
  ident: CR49
  article-title: Cleavage of DFNA5 by caspase-3 during apoptosis mediates progression to secondary necrotic/pyroptotic cell death
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms14128
– volume: 20
  start-page: 373
  year: 2020
  ident: CR43
  article-title: Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-020-01472-9
– volume: 11
  start-page: 6262
  year: 2020
  ident: CR67
  article-title: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19810-w
– volume: 25
  start-page: 815
  year: 2021
  end-page: 834
  ident: CR26
  article-title: Novel immune targets for the treatment of triple-negative breast cancer
  publication-title: Expert Opin. Ther. Targets
  doi: 10.1080/14728222.2021.2006187
– volume: 11
  start-page: 143
  year: 2011
  ident: CR29
  article-title: Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: Implications for treatment optimization
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-11-143
– volume: 22
  start-page: 1357
  year: 2021
  end-page: 1358
  ident: CR6
  article-title: Optimal adjuvant endocrine therapy for breast cancer
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(21)00420-4
– volume: 362
  start-page: 956
  year: 2018
  end-page: 960
  ident: CR11
  article-title: ESCRT-dependent membrane repair negatively regulates pyroptosis downstream of GSDMD activation
  publication-title: Science (New York)
  doi: 10.1126/science.aar7607
– volume: 36
  start-page: e24292
  year: 2022
  ident: CR62
  article-title: Pyroptosis patterns and immune infiltrates characterization in head and neck squamous cell carcinoma
  publication-title: J. Clin. Lab. Anal.
  doi: 10.1002/jcla.24292
– volume: 25
  start-page: 8159
  year: 2021
  end-page: 8168
  ident: CR47
  article-title: Caspase-3-mediated GSDME induced pyroptosis in breast cancer cells through the ROS/JNK signalling pathway
  publication-title: J. Cell Mol. Med.
  doi: 10.1111/jcmm.16574
– volume: 142
  start-page: 1444
  year: 2022
  end-page: 1455
  ident: CR17
  article-title: Repurposing melanoma chemotherapy to activate inflammasomes in the treatment of BRAF/MAPK inhibitor resistant melanoma
  publication-title: J. Investig. Dermatol.
  doi: 10.1016/j.jid.2021.09.030
– volume: 33
  start-page: 511
  year: 2022
  end-page: 521
  ident: CR66
  article-title: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2022.02.008
– volume: 30
  start-page: 44
  year: 2019
  end-page: 56
  ident: CR58
  article-title: Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy495
– volume: 68
  start-page: 394
  year: 2018
  end-page: 424
  ident: CR1
  article-title: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
– volume: 11
  start-page: 5155
  year: 2021
  end-page: 5183
  ident: CR45
  article-title: Chemoresistance in breast cancer: PI3K/Akt pathway inhibitors vs the current chemotherapy
  publication-title: Am. J. Cancer Res.
– volume: 23
  start-page: 743
  year: 2021
  end-page: 753
  ident: CR51
  article-title: Copy number variation in triple negative breast cancer samples associated with lymph node metastasis
  publication-title: Neoplasia (New York)
  doi: 10.1016/j.neo.2021.05.016
– volume: 10
  start-page: 650
  year: 2019
  ident: CR28
  article-title: The role of pyroptosis in cancer: Pro-cancer or pro-"host"?
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-019-1883-8
– volume: 102
  start-page: 15545
  year: 2005
  end-page: 15550
  ident: CR34
  article-title: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.0506580102
– volume: 14
  start-page: 6223
  year: 2021
  end-page: 6235
  ident: CR56
  article-title: Gasdermin D in different subcellular locations predicts diverse progression, immune microenvironment and prognosis in colorectal cancer
  publication-title: J. Inflamm. Res.
  doi: 10.2147/jir.S338584
– volume: 22
  start-page: 499
  year: 2021
  end-page: 511
  ident: CR64
  article-title: Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(20)30754-3
– volume: 79
  start-page: 3492
  year: 2019
  end-page: 3502
  ident: CR52
  article-title: Gaussian mixture models for probabilistic classification of breast cancer
  publication-title: Can. Res.
  doi: 10.1158/0008-5472.Can-19-0573
– volume: 29
  start-page: 241
  year: 2016
  end-page: 250
  ident: CR59
  article-title: The genomic landscape of breast cancer and its interaction with host immunity
  publication-title: Breast (Edinburgh)
  doi: 10.1016/j.breast.2016.07.015
– volume: 21
  start-page: 1353
  year: 2020
  end-page: 1365
  ident: CR68
  article-title: Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(20)30445-9
– volume: 40
  start-page: 264
  year: 2021
  ident: CR70
  article-title: Pyroptosis at the forefront of anticancer immunity
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-021-02065-8
– volume: 13
  start-page: 24379
  year: 2021
  end-page: 24401
  ident: CR61
  article-title: Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy
  publication-title: Aging
  doi: 10.18632/aging.203687
– volume: 34
  start-page: 2300
  year: 2013
  end-page: 2308
  ident: CR32
  article-title: Correlating transcriptional networks to breast cancer survival: A large-scale coexpression analysis
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgt208
– volume: 186
  start-page: 193
  year: 2022
  end-page: 195
  ident: CR36
  article-title: Revealing novel, latent subsets of patients with morphoea through principal component analysis
  publication-title: Br. J. Dermatol.
  doi: 10.1111/bjd.20748
– volume: 11
  start-page: 6175
  year: 2020
  ident: CR4
  article-title: Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19933-0
– volume: 7
  start-page: 1360
  year: 2021
  end-page: 1367
  ident: CR7
  article-title: Neoadjuvant trastuzumab, pertuzumab, and docetaxel vs trastuzumab emtansine in patients with ERBB2-positive breast cancer: A phase 2 randomized clinical trial
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2021.1932
– volume: 15
  start-page: 640
  year: 2014
  end-page: 647
  ident: CR2
  article-title: Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(14)70080-4
– volume: 9
  start-page: 780142
  year: 2021
  ident: CR12
  article-title: Treatment of severe acute pancreatitis and related lung injury by targeting gasdermin D-mediated pyroptosis
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.780142
– volume: 6
  start-page: 36107
  year: 2016
  ident: CR57
  article-title: Targeting inflammasome/IL-1 pathways for cancer immunotherapy
  publication-title: Sci. Rep.
  doi: 10.1038/srep36107
– volume: 69
  start-page: 363
  year: 2019
  end-page: 385
  ident: CR9
  article-title: Cancer treatment and survivorship statistics, 2019
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21565
– volume: 2022
  start-page: 4494713
  year: 2022
  ident: CR33
  article-title: Signature construction and molecular subtype identification based on pyroptosis-related genes for better prediction of prognosis in hepatocellular carcinoma
  publication-title: Oxid. Med. Cell. Longev.
  doi: 10.1155/2022/4494713
– volume: 14
  start-page: 6223
  year: 2021
  ident: 14897_CR56
  publication-title: J. Inflamm. Res.
  doi: 10.2147/jir.S338584
– volume: 12
  start-page: 453
  year: 2015
  ident: 14897_CR42
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.3337
– volume: 13
  start-page: 18608
  year: 2021
  ident: 14897_CR54
  publication-title: Nanoscale
  doi: 10.1039/d1nr05001j
– volume: 12
  start-page: 1535
  year: 2021
  ident: 14897_CR60
  publication-title: Genes
  doi: 10.3390/genes12101535
– volume: 31
  start-page: 549
  year: 2022
  ident: 14897_CR27
  publication-title: Expert Opin. Investig. Drugs
  doi: 10.1080/13543784.2022.2008354
– volume: 124
  start-page: 100
  year: 2017
  ident: 14897_CR37
  publication-title: Methods (San Diego)
  doi: 10.1016/j.ymeth.2017.06.010
– volume: 325
  start-page: 1804
  year: 2021
  ident: 14897_CR3
  publication-title: JAMA
  doi: 10.1001/jama.2021.1647
– volume: 69
  start-page: 363
  year: 2019
  ident: 14897_CR9
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21565
– volume: 22
  start-page: 499
  year: 2021
  ident: 14897_CR64
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(20)30754-3
– year: 2015
  ident: 14897_CR46
  publication-title: Semin. Cancer Biol.
  doi: 10.1016/j.semcancer.2015.03.001
– volume: 25
  start-page: 815
  year: 2021
  ident: 14897_CR26
  publication-title: Expert Opin. Ther. Targets
  doi: 10.1080/14728222.2021.2006187
– volume: 40
  start-page: 264
  year: 2021
  ident: 14897_CR70
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-021-02065-8
– volume: 226
  start-page: 152068
  year: 2021
  ident: 14897_CR24
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2021.152068
– volume: 24
  start-page: 377
  year: 2013
  ident: 14897_CR30
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mds280
– volume: 23
  start-page: 743
  year: 2021
  ident: 14897_CR51
  publication-title: Neoplasia (New York)
  doi: 10.1016/j.neo.2021.05.016
– volume: 495
  start-page: 1418
  year: 2018
  ident: 14897_CR55
  publication-title: Biochem. Biophys. Res. Commun.
  doi: 10.1016/j.bbrc.2017.11.156
– volume: 24
  start-page: 541
  year: 2018
  ident: 14897_CR23
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0014-x
– volume: 68
  start-page: 394
  year: 2018
  ident: 14897_CR1
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
– volume: 13
  start-page: e13452
  year: 2021
  ident: 14897_CR14
  publication-title: EMBO Mol. Med.
  doi: 10.15252/emmm.202013452
– volume: 9
  start-page: 780142
  year: 2021
  ident: 14897_CR12
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.780142
– volume: 18
  start-page: 187
  year: 2021
  ident: 14897_CR5
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-021-00471-7
– volume: 12
  start-page: 720877
  year: 2021
  ident: 14897_CR13
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.720877
– volume: 49
  start-page: D545
  year: 2021
  ident: 14897_CR35
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkaa970
– year: 2020
  ident: 14897_CR72
  publication-title: Science (New York).
  doi: 10.1126/science.aaz7548
– volume: 21
  start-page: 1353
  year: 2020
  ident: 14897_CR68
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(20)30445-9
– volume: 15
  start-page: 640
  year: 2014
  ident: 14897_CR2
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(14)70080-4
– volume: 18
  start-page: 123
  year: 2013
  ident: 14897_CR31
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2012-0397
– volume: 37
  start-page: 623
  year: 2020
  ident: 14897_CR8
  publication-title: Cancer Cell
  doi: 10.1016/j.ccell.2020.04.007
– volume: 148
  start-page: 382
  year: 2021
  ident: 14897_CR65
  publication-title: Eur. J. Cancer (Oxford)
  doi: 10.1016/j.ejca.2021.02.028
– volume: 14
  start-page: 989
  year: 2022
  ident: 14897_CR40
  publication-title: Aging
  doi: 10.18632/aging.203855
– volume: 11
  start-page: 5155
  year: 2021
  ident: 14897_CR45
  publication-title: Am. J. Cancer Res.
– volume: 16
  start-page: 172
  year: 2015
  ident: 14897_CR50
  publication-title: Nat. Rev. Genet.
  doi: 10.1038/nrg3871
– volume: 362
  start-page: 956
  year: 2018
  ident: 14897_CR11
  publication-title: Science (New York)
  doi: 10.1126/science.aar7607
– volume: 13
  start-page: 46
  year: 2017
  ident: 14897_CR22
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/nchembio.2229
– volume: 11
  start-page: 6175
  year: 2020
  ident: 14897_CR4
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19933-0
– volume: 522
  start-page: 171
  year: 2021
  ident: 14897_CR19
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2021.09.035
– volume: 36
  start-page: e24292
  year: 2022
  ident: 14897_CR62
  publication-title: J. Clin. Lab. Anal.
  doi: 10.1002/jcla.24292
– volume: 34
  start-page: 2300
  year: 2013
  ident: 14897_CR32
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/bgt208
– volume: 102
  start-page: 15545
  year: 2005
  ident: 14897_CR34
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.0506580102
– volume: 20
  start-page: 373
  year: 2020
  ident: 14897_CR43
  publication-title: Cancer Cell Int.
  doi: 10.1186/s12935-020-01472-9
– volume: 29
  start-page: 1243
  year: 2020
  ident: 14897_CR38
  publication-title: Stat. Methods Med. Res.
  doi: 10.1177/0962280219856238
– volume: 16
  start-page: e173
  year: 2015
  ident: 14897_CR44
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(14)71116-7
– volume: 33
  start-page: 511
  year: 2022
  ident: 14897_CR66
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2022.02.008
– volume: 10
  start-page: 4800
  year: 2020
  ident: 14897_CR53
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-020-61710-y
– volume: 10
  start-page: 650
  year: 2019
  ident: 14897_CR28
  publication-title: Cell Death Dis.
  doi: 10.1038/s41419-019-1883-8
– volume: 79
  start-page: 3492
  year: 2019
  ident: 14897_CR52
  publication-title: Can. Res.
  doi: 10.1158/0008-5472.Can-19-0573
– volume: 76
  start-page: 232
  year: 2019
  ident: 14897_CR20
  publication-title: Mol. Cell
  doi: 10.1016/j.molcel.2019.09.006
– volume: 265
  start-page: 130
  year: 2015
  ident: 14897_CR10
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12287
– volume: 12
  start-page: 650491
  year: 2021
  ident: 14897_CR25
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.650491
– volume: 26
  start-page: 101239
  year: 2019
  ident: 14897_CR48
  publication-title: Redox Biol.
  doi: 10.1016/j.redox.2019.101239
– volume: 2022
  start-page: 4494713
  year: 2022
  ident: 14897_CR33
  publication-title: Oxid. Med. Cell. Longev.
  doi: 10.1155/2022/4494713
– volume: 7
  start-page: 1360
  year: 2021
  ident: 14897_CR7
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2021.1932
– volume: 142
  start-page: 1444
  year: 2022
  ident: 14897_CR17
  publication-title: J. Investig. Dermatol.
  doi: 10.1016/j.jid.2021.09.030
– volume: 12
  start-page: 748221
  year: 2021
  ident: 14897_CR39
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.748221
– volume: 11
  start-page: 143
  year: 2011
  ident: 14897_CR29
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-11-143
– volume: 30
  start-page: 44
  year: 2019
  ident: 14897_CR58
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdy495
– volume: 29
  start-page: 241
  year: 2016
  ident: 14897_CR59
  publication-title: Breast (Edinburgh)
  doi: 10.1016/j.breast.2016.07.015
– volume: 25
  start-page: 356
  year: 2021
  ident: 14897_CR15
  publication-title: Crit. Care (London)
  doi: 10.1186/s13054-021-03775-3
– volume: 579
  start-page: 421
  year: 2020
  ident: 14897_CR71
  publication-title: Nature
  doi: 10.1038/s41586-020-2079-1
– volume: 186
  start-page: 193
  year: 2022
  ident: 14897_CR36
  publication-title: Br. J. Dermatol.
  doi: 10.1111/bjd.20748
– volume: 11
  start-page: 6262
  year: 2020
  ident: 14897_CR67
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-19810-w
– volume: 9
  start-page: 697832
  year: 2021
  ident: 14897_CR18
  publication-title: Front. Cell Dev. Biol.
  doi: 10.3389/fcell.2021.697832
– volume: 6
  start-page: 36107
  year: 2016
  ident: 14897_CR57
  publication-title: Sci. Rep.
  doi: 10.1038/srep36107
– volume: 12
  start-page: 763807
  year: 2021
  ident: 14897_CR63
  publication-title: Front. Genet.
  doi: 10.3389/fgene.2021.763807
– volume: 22
  start-page: 1357
  year: 2021
  ident: 14897_CR6
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(21)00420-4
– volume: 170
  start-page: 105748
  year: 2021
  ident: 14897_CR16
  publication-title: Pharmacol. Res.
  doi: 10.1016/j.phrs.2021.105748
– volume: 8
  start-page: 14128
  year: 2017
  ident: 14897_CR49
  publication-title: Nat. Commun.
  doi: 10.1038/ncomms14128
– volume: 13
  start-page: 24379
  year: 2021
  ident: 14897_CR61
  publication-title: Aging
  doi: 10.18632/aging.203687
– volume: 25
  start-page: 8159
  year: 2021
  ident: 14897_CR47
  publication-title: J. Cell Mol. Med.
  doi: 10.1111/jcmm.16574
– volume: 297
  start-page: 123
  year: 2020
  ident: 14897_CR21
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12908
– volume: 15
  start-page: 345
  year: 2022
  ident: 14897_CR41
  publication-title: J. Inflamm. Res.
  doi: 10.2147/jir.S349186
– volume: 10
  start-page: 1865670
  year: 2021
  ident: 14897_CR69
  publication-title: Oncoimmunology
  doi: 10.1080/2162402x.2020.1865670
SSID ssj0000529419
Score 2.415973
Snippet Understanding the association of pyroptosis with tumor progression, prognosis and effect on immunotherapeutic response in breast cancer (BC) is limited. This...
Abstract Understanding the association of pyroptosis with tumor progression, prognosis and effect on immunotherapeutic response in breast cancer (BC) is...
SourceID doaj
pubmedcentral
proquest
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
Publisher
StartPage 10640
SubjectTerms 631/250
631/67/1347
692/4028
692/499
Breast cancer
Humanities and Social Sciences
Immunosuppressive agents
Immunotherapy
Infiltration
Medical prognosis
Metastases
multidisciplinary
Mutation
p53 Protein
Patients
Prognosis
Pyroptosis
Science
Science (multidisciplinary)
Tumor microenvironment
Tumors
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dSxwxEA9FEPpSqm3ptSop9K0GN8lusnlUUaTQPlXwLeSTHujucbsn-N93kt273grqi4-7yZJNZiYzk8z8BqHv3jlhFfXEemVJGQIjJjBLJIOdEHjE-pxf8eu3uLouf95UN1ulvlJM2AAPPCzciSwrGqNw0aYcSGGsCz7aBKECvltkGecTdN6WMzWgejNVUjVmyRS8PulAU6VsMvC9wANQktCJJsqA_RMr83GM5KOL0qx_Lt-jd6PhiE-HH95Db0Kzj3aHUpIPH9D9kHEbxyM43Ea8eFi2i77t5h3OGSvB425l05lrh03jcb-6a5f4LkXkbaW7YWC5-e0IpovdFM8ZGrFNYew9doldlh_R9eXFn_MrMtZUIK6isieVMKCypKEqKmdVGcHBY8YEWXigZklNIZivHZcRTC_lJFXBelorzyMzhTf8E9pp2iZ8RlhV0RoDFgBVNTgxDh6cCNzZWhTRczZDdL2-2o2A46nuxa3OF9-81gNNNNBEZ5poOkM_Nt8sBriNZ3ufJbJteiao7PwCGEiPDKRfYqAZOlgTXY_y22kmpFKSVxKav22aQfLSdYppQrtKfWqat8BqhuSEWSY_NG1p5n8zhrcCs7dIgx-v2er_4E9P-MtrTPgresuSGBSCMH6AdvrlKhyCZdXboyxE_wDfGSQ0
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA86EXwRP7FuSgTfNKxJ2nw8DRXHEPTJwX0L-dQLW3vX9gr7703S3Ds7cI9tUtL2nJOcz98B4L2zlhmJHTJOGtR4T5D2xCBO4k4YecS4XF_x_Qc7O2--rdpVcbiNJa1ytyfmjdr1NvnIjwnjUnLacnqyuUKpa1SKrpYWGvfBgwRdlriar_jex5KiWA2WpVampuJ4jOdVqimLFli0AyRHeHEeZdj-ha55O1PyVrg0n0KnT8Djoj7CTzO9n4J7vnsGHs4NJa-fgz9z3W0ojjjYB7i5HvrN1I_rEea6Fe_guDXJ8zpC3Tk4bS_7AV6mvLx_it5gZLz1RYHUhXaJ6hwHoUnJ7BO0iWmGF-D89OvPL2eodFZAtsV8Qi3T8eDiGssgrZFNiGYe0drz2kWaNljXjDhhKQ9RAZOWY-mNw0I6GoiunaYvwUHXd_4VgLINRuuoB2Apoilj44VlnlojWB0cJRXAu_-rbIEdT90vLlQOf1OhZpqoSBOVaaJwBT7sn9nMoBt3zv6cyLafmQCz841--KWK_CnetDgEZoNJpbRMG-tdMAmJRwgRCK3A0Y7oqkjxqG54rgLv9sNR_lJQRXe-36Y5AueNsK0AXzDL4oWWI936d0byllH5rdPiH3dsdbP4_z_49d3veggekcTgNUOEHoGDadj6N1FzmszbLB5_AVVgG0w
  priority: 102
  providerName: ProQuest
– databaseName: HAS SpringerNature Open Access 2022
  dbid: AAJSJ
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEA_HHYIv4ieunhLBNy02SZs0j6t4HAv6ogf3FvKpC3ft0naF---dpOlqDxV8bJOQtPNLZiaZ-QWh185abiRxhXHSFJX3tNCemkJQWAkBI8al_IpPn_n5RbW5rC-PEJ1zYVLQfqK0TMv0HB32bgBFE5PBwHUCA16KAjyek0jVDtg-Wa83XzaHnZV4dlURmTNkStb8ofFCCyWy_oWFeTs-8tYhadI9Z_fRvWw04vU0zAfoyLcP0Z3pGsmbR-jHlG0b8vYb7gLe3fTdbuyG7YBTtop3eNibuN86YN06PO6vux5fx2i831LdMMBte5WJdLFdcjlDITYxhH3ENkKlf4wuzj5-_XBe5PsUClsTMRY116CuhCYySGtkFcC5o1p7UTqQZEV0yalrLBMBzC5pBZHeONJIxwLVpdPsCTpuu9Y_RVjWwWgN2p_IBhwYCw-We2ZNw8vgGF0hMv9fZTPZeLzz4kqlQ2_WqEkmCmSikkwUWaE3hza7iWrjn7XfR7Edakaa7PSi67-pDBsF-CAhcBtMTKDl2ljvgon8O-D4B8pW6HQWuspzd1CUCykFqwUUvzoUw6yLRym69d0-1mlIWv7qFRILsCwGtCxpt98Tf7cEk7eMnb-dYfWr879_8LP_q_4c3aUR8CUvKDtFx2O_9y_AfhrNyzxhfgJzYBph
  priority: 102
  providerName: Springer Nature
Title Identification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancer
URI https://link.springer.com/article/10.1038/s41598-022-14897-1
https://www.proquest.com/docview/2679973573
https://www.proquest.com/docview/2681040045
https://pubmed.ncbi.nlm.nih.gov/PMC9226023
https://doaj.org/article/7451ff6cfb43436abcedfb2635888f23
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwELfGJiReEJ-iMCoj8QaB2Ens-AGhrto0VdqEgEp9i_w5KnVJSVJE_3vOTlrINBBPUWIndnx3vjvb9zuEXhutmRLERMoIFaXW0khaqiJOYSYEHlEmxFdcXLLzeTpbZIsDtEt31A9gc6tr5_NJzevVu5_ftx9B4D90IeP5-waUkA8UA7cKjHvBI_CGjkAzcZ_R4KI39zusbyrSkOvDg7BHYEzQPo7m9s8MdFWA9B_YoTdPUd7YSg0a6uwBut-blnjS8cJDdGDLR-hul2xy-xj96GJyXb9IhyuH19u6WrdVs2xwiGmxBjcb5VdlGyxLg9vNdVXja39m74-AOAzDtFz1cLtYDxGfoRArf9C9xdozVP0Ezc9Ov07Poz7rQqQzwtsoYxKUGpdEOKGVSB24gFRKy2MD9E6JjBk1uU64A-NMaE6EVYbkwiSOytjI5Ck6LKvSPkNYZE5JCZQgIgc3R8ONZjbRKmexMwkdIbIb30L3kOQ-M8aqCFvjSV50NCmAJkWgSUFG6M3-nXUHyPHP2ieebPuaHkw7PKjqq6KXzYKnGXGOaad8mC2TSlvjlEfpyfPc0WSEjndEL3YMWlDGheBJxqH41b4YZNNvuMjSVhtfJydhksxGiA-YZdChYUm5_BZQvgUYxrFv_O2OrX43_vcffv4fnXmB7lHP5TEDEThGh229sS_BtGrVGN3hCz5GR5PJ7MsMrienl58-w9Mpm47DcsU4SNQvXagoDQ
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKEYIL4qkuFDASnCBqbCdxfECIV7Wlj1Mr9Wb8hJXaZNlkQfun-I2MnWRLKtFbj4md-DGfxzMezwxCr6wxhRbEJtoKnWTO0UQ5qhNOgRMCRrSN_hWHR8X0JPt6mp9uoD-DL0y4VjnwxMiobW3CGfkOLbgQnOWcvZ__TELWqGBdHVJodLDYd6vfoLI17_Y-A31fU7r75fjTNOmzCiQmJ7xN8kIB0-aKCC-MFpkHFYcq5XhqYTwZUWlBbWkY9yB8CMOJcNqSUljmqUqtYvDfG-gmbLxpUPb4KV-f6QSrWUZE75uTsnKngf0x-LCBxgd6h-AJGe1_MU3ASLa9fDPzknk27nq799DdXlzFHzp83UcbrnqAbnUJLFcP0a_Oz9f3B3-49ni-WtTztm5mDY5-Ms7iZqnDSW-DVWVxuzyvF_g83AP8x8kOA9BnZ30IX2zGUaShEOtweb7FJoB08QidXMucP0abVV25LYRF7rVSIHcQUYLqZODBFI4ZXRapt4xOEBnmV5o-zHnItnEmo7mdlbKjiQSayEgTSSbozfqbeRfk48raHwPZ1jVDgO74ol58l_16lzzLifeF8Tq47hZKG2e9DpF_yrL0lE3Q9kB02XONRl5gfIJerothvQcjjqpcvQx1ShIZbz5BfASWUYfGJdXsR4wcLkDYTkPjbwdYXTT-_wE_ubqvL9Dt6fHhgTzYO9p_iu7QAPa0SCjbRpvtYumegdTW6udxqWD07brX5l8P1Fit
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKViAuiKe6UMBIcIKosZ3E8QEhSrtqKawqRKXejJ-wUpssmyxo_xq_jnEeW1KJ3npM7Dznm_GM54XQS2tMpgWxkbZCR4lzNFKO6ohTkISAEW2b_IrP0-zgJPl4mp5uoD99LkwIq-xlYiOobWnCHvkOzbgQnKWc7fguLOJ4b_Ju_jMKHaSCp7Vvp9FC5MitfoP5Vr093ANav6J0sv_1w0HUdRiITEp4HaWZAgHOFRFeGC0SD-YOVcrx2MK3JUTFGbW5YdyDIiIMJ8JpS3JhmacqtorBfW-gTR6sohHa3N2fHn9Z7_AEH1pCRJepE7N8p4LVMmS0gf0HVojgERmshk3TgIGmezlO85KztlkDJ3fRnU55xe9btN1DG664j2627SxXD9CvNuvXd9uAuPR4vlqU87qsZhVusmacxdVSh33fCqvC4np5Xi7weYgK_CflDgPsZ2ddQV9shjWlYRDrEEpfYxMgu3iITq7lrz9Co6Is3BbCIvVaKdBCiMjBkDJwYDLHjM6z2FtGx4j0_1earuh56L1xJhvnO8tlSxMJNJENTSQZo9fra-ZtyY8rZ-8Gsq1nhnLdzYly8V123C95khLvM-N1SOTNlDbOeh3qAOV57ikbo-2e6LKTIZW8QPwYvVgPA_cHl44qXLkMc3LSiOF0jPgALIMXGo4Usx9NHXEBqnccHv6mh9XFw___wY-vftfn6Bbwpfx0OD16gm7TgPU4iyjbRqN6sXRPQYWr9bOOVzD6dt3s-RfHyF5I
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+pyroptosis+related+subtypes+and+tumor+microenvironment+infiltration+characteristics+in+breast+cancer&rft.jtitle=Scientific+reports&rft.au=Huang%2C+Guo&rft.au=Zhou%2C+Jun&rft.au=Chen%2C+Juan&rft.au=Liu%2C+Guowen&rft.date=2022-06-23&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft.spage=10640&rft_id=info:doi/10.1038%2Fs41598-022-14897-1&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon